Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd. (GLMD): 2 pipeline candidates · 1 upcoming catalyst · 8 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
N/A
0% dilution
Lead: Phase 1
2 candidates
1 upcoming, next in ~377d
N/A
A transparent, data-derived signal for Galmed Pharmaceuticals Ltd.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$4.0M
Cash
$4.0M
Quarterly Burn
—
Runway
—
Revenue
—
Cash Runway vs Catalysts
Upcoming catalyst timeline.
Pipeline (2 candidates)
| Drug | Phase |
|---|---|
| aramchol | Phase 1 |
| aramchol free acid | Phase 1 |
Upcoming Catalysts (1)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
15
Total value held
$70K
| Holder | Shares | Value |
|---|---|---|
| two sigma investments, lp | 80,177 | $39K |
| xtx topco ltd | 22,396 | $11K |
| jane street group, llc | 16,445 | $8K |
| two sigma securities, llc | 11,971 | $6K |
| citadel advisors llc | 11,382 | $6K |
| bnp paribas financial markets | 600 | $294 |
| morgan stanley | 157 | $77 |
| wells fargo & company/mn | 43 | $21 |
| sbi securities co., ltd. | 16 | $8 |
| federation des caisses desjardins du quebec | 14 | $7 |
Showing top 10 of 15 institutional holders of Galmed Pharmaceuticals Ltd.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Galmed Pharmaceuticals Ltd.'s pipeline?
Galmed Pharmaceuticals Ltd. (GLMD) has 2 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Galmed Pharmaceuticals Ltd.'s lead drug candidate?
Galmed Pharmaceuticals Ltd.'s most advanced tracked candidate is aramchol (Phase 1) for Healthy; Primary Sclerosing Cholangitis.
What is Galmed Pharmaceuticals Ltd.'s next catalyst?
Galmed Pharmaceuticals Ltd.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 3, Multinational, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study t" — expected June 30, 2027.
What is Galmed Pharmaceuticals Ltd.'s market capitalization?
Galmed Pharmaceuticals Ltd.'s market capitalization is approximately $4.0M.
Who is the CEO of Galmed Pharmaceuticals Ltd.?
Mr. Allen Baharaff is the chief executive officer of Galmed Pharmaceuticals Ltd. (GLMD).
Get the full picture on Galmed Pharmaceuticals Ltd.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.